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Background: Diabetes mellitus (DM) is a major cause of illness and death in the United States,
and diabetic patients are at increased risk for burn injury. We therefore sought to examine
the impact of pre-existing DM on the risk of inpatient mortality and hospital acquired
infections (HAI) among burn patients.
Methods: Adult patients (18 years old) admitted from 2004 to 2013 were analyzed. Weighted
Kaplan–Meier survival curves – adjusting for patient demographics, burn mechanism,
presence of inhalation injury, total body surface area, additional comorbidities, and
differential lengths of stay– were used to estimate the 30-day and 60-day risk of mortality and
HAIs.
Results: A total of 5539 adult patients were admitted and included in this study during the
study period. 655 (11.8%) had a pre-existing DM. The crude incidence of HAIs and in-hospital
mortality for the whole burn cohort was 8.5% (n=378) and 4.4% (n=243), respectively. Diabetic
patients were more likely to be older, female, have additional comorbidities, inhalational
injury, and contact burns. After adjusting for patient and burn characteristics, the 60-day risk
of HAI among patients with DM was significantly higher, compared to non-diabetic patients
(RR 2.07, 95% CI 1.28, 6.79). However, no significant difference was seen in the 60-day risk of
mortality (RR 1.34, 95% CI 0.44, 3.10).
Conclusions: Pre-existing DM significantly increases the risk of developing an HAI in patients
following burn injury, but does not significantly impact the risk of inpatient mortality.
Further understanding of the immune modulatory mechanism of burn injury and DM is
imperative to better attenuate the acquisition of HAIs.
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1. Introduction
Diabetes mellitus (DM) affects roughly 12% of adults in the 
United States, or 29.1 million people, and represents a major 
burden to the healthcare system. The cost of DM care due to 
increased health care utilization and lost productivity was 
approximately $245 billion in 2012 [1]. Over the past 3 decades, 
the prevalence of adults diagnosed with DM in the US has 
increased substantially [2]. Diabetics are at increased risk for 
burn injury due to peripheral neuropathy, which is associated 
with decreased sensory and motor function and leads to 
the inability to quickly withdraw extremities from heat source 
[3–5]. Subsequently, a substantial proportion of patients 
admitted to burn centers are diabetic [6].
Burn injuries are often associated with complications, even 
in otherwise healthy individuals. Diabetics may be at 
increased risk for complications and mortality. For example, 
diabetics have a predilection for atherosclerotic occlusion in 
small and large vessels thus facilitating development of 
ischemic extremities. Diabetics also exhibit wound repair 
failures and infections [5,7,8]. This is commonly attributable to 
microangiopathy and altered neutrophil migration [9] with 
reduced bacteriocidal activity and impaired phagocytosis 
[10,11]. With increased longevity of the US population and 
the concomitant rise in the number of diagnosed diabetics, it is 
likely that the number of diabetics admitted to the hospital 
following burn that may indicate intensive medical or surgical 
care will also increase. While existing data suggests that tight 
glycemic control following burn injury improves complication 
and mortality rates, it is unclear whether pre-existing DM 
impacts patient outcomes after burn injury [12,13].
Thus, the primary objective of this study is to estimate the 
impact of diabetes on the risk of hospital acquired infections 
(HAIs) and inpatient mortality after being hospitalized for burn 
injury.
2. Methods
Patients were identified using the North Carolina Jaycee Burn
Center registry, which consists of data collected on all
admitted patients in real-time for reporting to the National
Burn Repository. Adult (18 years old) patients admitted with
burn injury including inhalation injury only between January
1, 2004 and December 31, 2013, were eligible for inclusion. Only
a patient’s first hospitalization, for their first burn, within the
time period was included for analysis.
Registry data was then linked to the Carolina Data
Warehouse for Health (CDW-H), which is a central repository
for clinical and administrative data from the entire UNC
Healthcare System, which includes the Jaycee Burn Center
[14]. Registry data were validated using CDW-H data and
manual chart review. Missing and illogical registry data were
abstracted using similar methods. Patients were excluded if
discharge date could not be determined (n=37).
Diabetes mellitus was identified using both the comorbid-
ities recorded in the burn registry and International Statistical
Classification of Diseases and Related Health Problems (ICD-9)
diagnostic codes attached to the inpatient billing records
(ICD-9-CM 250). Mortality during the inpatient hospitalization
was also captured using both the registry and CDW-H records.
Hospital-acquired infections (HAIs) were identified using
the UNC Hospital Epidemiology database, which documents
HAIs identified through real-time, hospital-wide surveillance.
Surveillance is performed in accordance with the Centers of
Disease Control and Prevention (CDC) criteria and definitions
[15]. Only a patient’s first HAI was included in analyses.
Bivariate analyses comparing demographics, comorbid-
ities, burn characteristics, and patient outcomes (inpatient
mortality, HAIs, length of stay) between diabetic and non-
diabetic patients were performed using Chi-square and
Wilcoxon–Mann–Whitney tests, where appropriate. Comor-
bidities were identified using inpatient ICD-9-CM diagnostic
codes and included prior myocardial infarction (412–412.9),
congestive heart failure (428–428.9), peripheral vascular dis-
ease (441–441.9, 443.9, 785.4, and V43.4), cerebrovascular
disease (438–438.9), pulmonary disease (490.0–496.9, 500–
505.9, and 506.4), and renal disease (582–582.9, 583–583.7,
585–586.9, and 588–588.9). Yearly admit rates of diabetic
patients were calculated using Poisson regression. A p-
value<0.05 was considered statistically significant. Revised
Baux scores were calculated as described by Osler et al. [16].
Multivariable linear regression, adjusting for demographics,
comorbidities, and burn characteristics, was used to estimate
the average effect diabetes had on length of stay.
Kaplan–Meier survival curves were used to estimate the
cumulative 30-day and 60-day risks of mortality among
patients with and without DM. An Aalen-Johansen estimator
was used to estimate the 30-day and 60-day cumulative
incidence of HAIs in order to account for mortality as a
competing risk [17]. Both risk differences (RDs) and risk ratios
(RRs) were calculated. Only patients admitted for at least 2days
(i.e. at risk for an HAI as per CDC criteria) were included in HAI
analyses. Weighted survival curves were used to estimate the
standardized, cumulative 30-day and 60-day risk for both
mortality and HAIs [18,19]. Standardized estimates were
adjusted using inverse-probability of treatment weights
(IPTW) to account for confounding and inverse-probability
of censoring weights to account for potentially informative
censoring.
Briefly, the IPTW for each patient was estimated using
logistic regression which modeling the probability of DM using
admit year (categorized into tertiles, 2004–2007, 2008–2010, and
2011–2013), patient age (modeled as a linear spline with knots
at 30, 45, 60, and 75 years old), gender, race/ethnicity,
comorbidities, burn mechanism, total burn surface area
(modeled as a linear spline with knots at 20, 35, 50 and 65),
and inhalational injury. Weights were stabilized using the
marginal (i.e. overall) probability of having diabetes in the
cohort. The inverse-probability of censoring weights was also
estimated using logistic regression. The probability of censor-
ing (i.e. being discharged alive) was estimated using DM status
and all covariates included in the IPTW model. These weights
were also stabilized using the marginal probability of being
censored. Weights were then multiplied together to obtain a
final weight for each patient and truncated at 5% and 95%.
Confidence intervals for both the crude and standardized
cumulative incidence measures were calculated using a
nonparametric bootstrap. Specifically, 500 resamples with
replacement were conducted and the RD and RR were
calculated using the above procedures. The 95% confidence
intervals (CI) were determined using the 2.5 and 97.5 percentile
cut points for each effect estimate.
All analyses were performed using SAS 9.4 (SAS Inc., Cary,
NC). Institutional Review Board (IRB) approval was obtained
from the University of North Carolina.
3. Results
5539 patients met the inclusion criteria. 655 (11.8%) had a
diabetes mellitus (DM) diagnosis. A significant increase in the
proportion, and absolute number, of diabetic patients treated
has increased over time, p=0.01. Diabetic patients were
significantly more likely to be female (34.1% vs. 26.6%,
p<0.0001), African American (36.9% vs. 26.0%, p<0.0001),
older (median age 56.7 years old vs. 39.9 years old, p<0.0001),
and have comorbidities (40.3% vs. 10.6%, p<0.0001) compared
to non-diabetic patients (Table 1). Additionally, diabetic
patients were more likely to have contact burns (8.9% vs.
4.7%, p0.0001) and inhalational injury (11.0% vs. 8.1%,
p=0.01). Although the incidence of flame was similar in
diabetics and non-diabetics, the association of inhalational
injury is situational and likely not related to diabetic
comorbidity. No differences were seen in median burn size
(4.0% vs. 4.0%, p=0.44). Due to the older age of diabetic patients
and higher incidence of inhalational injury, the median
revised Baux scores was substantially higher among diabetics
(64.0 vs. 47.6), p<0.0001.
One-third (n=1838) of patients were admitted to the
intensive care unit (ICU); patients with DM were more likely
to be admitted to the burn ICU (40.3% vs. 32.3%, p<0.0001).
However, after adjusting for patient and burn characteristics,
no significant difference in the odds of ICU admission was seen
in diabetic patients (OR 1.03, 95% CI 0.81, 1.30), p=0.81. Patients
with diabetes were hospitalized for a median 11days (inter-
quartile range [IQR] 4–26), compared to a median 7days (IQR 2–
13) for patients without diabetes, p<0.0001. Even after
adjusting for patient demographics, comorbidities, and burn
characteristics, patients with diabetes were hospitalized for,
on average, 3.3days longer (95% confidence interval [CI] 1.21,







Hospitalization year, n (%)
2004–2007 155 (23.7) 1354 (27.7) 0.03
2008–2010 181 (27.6) 1410 (28.9) 0.51
2011–2013 319 (48.7) 2120 (43.4) 0.01
Gender, n (%)
Male 432 (66.0) 3588 (73.5) <0.0001
Female 223 (34.1) 1296 (26.6) –
Race/ethnicity, n (%)
African American 234 (36.9) 1233 (26.0) <0.0001
Caucasian 311 (49.1) 2651 (56.0) 0.001
Hispanic 22 (3.5) 287 (6.1) 0.009
Other 67 (10.6) 567 (12.0) 0.31
Unknown 21 146
Age, in years, median (IQR) 56.7 (48.3–66.2) 39.9 (28.5–52.3) <0.0001
Comorbidities, n (%)
Myocardial infarction 58 (8.9) 82 (1.7) <0.0001
Congestive heart failure 76 (11.6) 64 (1.3) <0.0001
Peripheral vascular disease 53 (8.1) 28 (0.6) <0.0001
Cerebrovascular disease 22 (3.6) 32 (0.7) <0.0001
Pulmonary disease 114 (17.4) 365 (7.5) <0.0001
Renal disease 86 (13.1) 55 (1.1) <0.0001
Burn mechanism, n (%)
Flame 343 (52.5) 2604 (53.6) 0.65
Scald 197 (30.2) 1508 (31.0) 0.68
Contact 58 (8.9) 230 (4.7) <0.0001
Other burn 55 (8.4) 519 (10.7) 0.08
Unknown 2 23
TBSA, median (IQR) 4.0 (2–9) 4.0 (2–10) 0.44
Baux score, median (IQR) 64.0 (53.6–77.3) 47.6 (34.4–62.5) <0.0001
Inhalation injury, n (%)
Yes 72 (11.0) 394 (8.1) 0.01
No 583 (89.0) 4489 (91.9) –
Abbreviations: DM, diabetes mellitus; IQR, interquartile range; TBSA, total burn surface area.
a Chi-square and Wilcoxon–Mann–Whitney tests were used to calculate p-values; p<0.05 are in bold.
5.38). Only 242 patients (4.4%) were hospitalized longer than
60days and administratively censored prior to discharge or
death.
Overall, 243 (4.4%) died during their inpatient hospitali-
zation. The unadjusted cumulative mortality rates for both
diabetic and non-diabetic patients are depicted in Fig. 1a. No
significant differences were seen at the 30-day or 60-day
cumulative incidence (Table 2). The 60-day cumulative
mortality among patients with DM was 16.2%, compared to
13.9% among patients without DM (RR 1.17, 95% CI 0.68, 1.90).
After adjusting for confounding and potentially informative
censoring through weighting, there was still no significant
difference in the 30-day and 60-day mortality rates (Fig. 1b).
After 30 days, diabetic patients had a lower mortality risk (RR
0.54, 95% CI 0.08, 2.28) and, after 60 days, a higher risk of
mortality (RR 1.34, 95% CI 0.44, 3.10) compared to non-
diabetic patients but both were not statistically significant
(Table 2).
Of the 4,426 patients (79.9%) hospitalized for at least 2days
and at risk for infection, 378 (8.5%) developed at least one HAI.
Among patients with an HAI, skin infections (n=127, 33.6%)
were the most common, followed by respiratory infections
(n=95, 25.1%), bloodstream infections (n=72, 19.1%), and
urinary tract infections (n=67, 17.2%). While more diabetic
patients developed at least one HAI (9.9% vs. 6.4%, p=0.0008),
no significant difference in the overall number of infections,
among those with at least one HAI, were seen between the two
groups (p=0.96).
The unadjusted cumulative incidence of HAIs is depicted in
Fig. 2a. No significant differences were seen between the two
Fig. 1 – (A) Crude and (B) stabilized 60-day cumulative incidence of inpatient mortality among patients with diabetes (dashed)
and without diabetes (solid).
Fig. 2 – (A) Crude and (B) stabilized 60-day cumulative risk of hospital-acquired infection (HAI) among patients with diabetes
(dashed) and without diabetes (solid) among adult burn patients admitted to the unit for 2 days.
Table 2 – Crude and standardized 60-day risk of mortality by diabetes mellitus (DM) status among adult burn patients.
Mortality, % Risk difference 95% CIa Risk ratio 95% CIa
DM No DM
Crude
30-day 6.9 5.1 0.02 0.01, 0.05 1.34 0.77, 2.12
60-day 16.2 13.9 0.02 0.05, 0.11 1.17 0.68, 1.90
Standardizedb
30-day 3.2 5.8 0.03 0.11, 0.03 0.54 0.08, 2.28
60-day 9.3 7.0 0.02 0.06, 0.13 1.34 0.44, 3.10
Abbreviations: DM, diabetes mellitus; CI, confidence interval.
a CIs determined using 2.5 and 97.5 percentile cutpoints from 500 nonparametric bootstrap resamples.
b Standardized for admit year (categorized into tertiles, 2004–2007, 2008–2010, and 2011–2013), patient age (modeled as a linear spline with knots at
30, 45, 60, and 75 years old), gender, race/ethnicity, comorbidities, burn mechanism, total burn surface area (modeled as a linear spline with knots at
20, 35, 50 and 65), and inhalational injury.
groups. After 30 days, the crude cumulative incidence of HAIs
among diabetic patients was lower (RR 0.60, 95% CI 0.36, 2.03);
after 60days the cumulative incidence of HAIs was higher
among diabetic patients (RR 1.26, 95% CI 0.80, 2.73) (Table 3).
After adjusting for confounding and differential hospitaliza-
tion lengths, patients with DM were significantly more likely to
have at least one HAI after 60days (Fig. 2b). Specifically, after
60 days, patients with DM were over 2 times more likely (95% CI
1.28, 6.79) to get an infection, compared to non-diabetics
(Table 3). Similarly, while patients with DM were also more
likely to have an HAI at 30-days, the result was not significant
(RR 1.67, 95% CI 0.74, 10.79).
4. Discussion
In this study, we found that pre-existing DM increased the risk 
of developing an HAI, even after adjusting for patient 
demographics, additional comorbidities, burn characteristics, 
and differential lengths of stay. However, despite the in-
creased risk of HAIs, no difference in the risk of inpatient 
mortality was seen. Our findings support previous research 
which found that DM increased the average length of stay and 
the incidence of complications (which include infections) [20–
23].
Memmel et al. found that the diabetic burn population was 
more susceptible to infections compared to non-diabetic 
patients (14.9% vs 8.1%, P<0.001). In addition, others have 
found diabetic patients had higher incidences of bacteremia 
(9.2% vs 2.5%), urinary tract infection (11% vs. 3%), pneumonia 
(9.2% vs. 6.3%), burn wound cellulitis (27% vs. 11%), and 
nosocomial burn wound infection (8% vs. 4%) [24]. Diabetic 
patients have predisposition for both acute and chronic 
infections. Previous studies have linked skin/soft tissue 
infections [25] and pulmonary infections [26] to chronic 
hyperglycemia. Interestingly, multiple organisms are have 
been found in diabetic burn wounds, with the most common 
organism being Staphylococcus aureus, whereas single organ-
isms are more likely to infect wounds in non-diabetic 
individuals [24,27].
While we found no difference in inpatient mortality 
between patients with and without DM, previous studies in 
trauma patients have been mixed. In a retrospective analysis
of the National Trauma Data Bank, Liou et al. found that DM
was an independent predictor of higher mortality [28]. On the
other hand in a systematic review of complications and
outcomes of diabetic patients with burn trauma, diabetic
patients had a higher odds of sustaining wound infections,
local infections and urinary tract infection. However,
diabetic patients did not have higher odds of mortality
[29]. Early burn mortality is attributable to acute infections
leading to sepsis, however early excision and grafting and
the use of ICU protocols such as ventilator and sepsis bundles
has led to the reduction of early sepsis associated burn
mortality [30].
The body’s response following burn injury has been
described in two phases, resuscitation and hypermetabolic.
It is during the hypermetabolic state that burn patients
develop insulin resistance and hyperglycemia, and contribute
to the increase morbidity and mortality seen in burn patients
[31]. Advancement over the last three decades in burn care
such growth hormones [32], use of B-blockers [33,34], and
testosterone [35] have helped attenuate the burn hypermeta-
bolic response; however, there still remains a challenge to
combat stress-induced hyperglycemia that may be magnified
in patients with pre-existing DM [36].
Potential strategies to mitigate poor outcomes in burn
patients with pre-existing diabetes include glycemic control
with insulin therapy, vigilant wound management, and the
early recognition of sepsis. For hyperglycemia associated with
the hypermetabolic response, maintaining blood glucose
levels below 110mg/dl with intensive insulin therapy are
recommended, but care should be taken to prevent hypogly-
cemia (i.e blood glucose<60mg/dl). In severely burned
pediatric patients, a target blood glucose of 130mg/dl is
suggested to prevent the additional risk and detrimental
outcomes from hypoglycemia [37]. Alternative therapies such
as metformin and fenofibrate may be utilized with monitoring
for unwanted side effects, like lactic acidosis [38,39]. Early
intervention in cases of sepsis in burned diabetic patients is
imperative to reduce progression to septic shock and increase
mortality [40]. Our widespread adoption of appropriate
glycemic control and early recognition and treatment of sepsis
using goal-directed therapy and ICU sepsis bundles may
explain why we did not find a significant increase in inpatient
mortality among diabetics in our study.
Table 3 – Crude and standardized 60-day cumulative incidence of hospital-acquired infections (HAIs) by diabetes mellitus
(DM) status among adult burn patients.
HAI incidence, % Risk difference 95% CIa Risk ratio 95% CIa
DM No DM
Crude
30-day 12.1 20.2 0.08 0.18, 0.18 0.60 0.36, 2.03
60-day 41.8 33.2 0.09 0.07, 0.59 1.26 0.80, 2.73
Standardizedb
30-day 18.6 11.1 0.07 0.03, 0.39 1.67 0.74, 10.79
60-day 31.8 15.4 0.15 0.04, 0.84 2.07 1.28, 6.79
Abbreviations: HAI, hospital-acquired infection; DM, diabetes mellitus; CI, confidence interval
a CIs determined using 2.5 and 97.5 percentile cutpoints from 500 nonparametric bootstrap resamples.
b Standardized for admit year (categorized into tertiles, 2004–2007, 2008–2010, and 2011–2013), patient age (modeled as a linear spline with knots at
30, 45, 60, and 75 years old), gender, race/ethnicity, comorbidities, burn mechanism, total burn surface area (modeled as a linear spline with knots at
20, 35, 50 and 65), and inhalational injury.
This study is not without limitations. First, pre-existing
diabetes and comorbidities were identified using ICD-9 codes,
which likely underestimates the true incidence and may be
subject to interpretation. Furthermore, we do not have
glycated hemoglobin levels to determine level of preexisting
diabetic control. Second, only inpatient mortality was able to
be measured and represents on a portion of all deaths caused
by burn injury. Future studies should include measures of
long-term morbidity and mortality outside of the initial
hospitalizations. Patients were also observed for differing
lengths of time and could be associated with both the risk of
HAI and inpatient mortality. However, inverse-probability of
censor weighting was used to account for differing lengths of
stay in order to minimize this potential bias. We were also able
to account for the potential confounding by age, additional
comorbidities, and burn characteristics using treatment
weights, which allows us to estimate the direct effect of
diabetes on inpatient mortality and HAIs (assuming no
unmeasured confounding variables). Finally, this analysis
only includes patients from one burn center, and results may
not be generalizable to other hospitals.
5. Conclusion
Pre-existing diabetes mellitus significantly increases the risk
of developing hospital-acquired infections, but does not
increase inpatient mortality following burn injury. Our
findings emphasize that advancements in burn care such as
early insulin use and appropriate glycemic control to prevent
burn mortality in diabetic patients and improve other burn
outcomes have been successful. However, further under-
standing of the immune modulatory mechanism of burn
injury and diabetes mellitus is imperative to better attenuate
the acquisition of hospital-acquired infections.
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